US Bancorp’s Voyager Therapeutics VYGR Stock Holding History

US Bancorp’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-284	Closed	-$2K	–	3972
2020 Q4	$2K	Hold	284	–	–	﹤0.01%	3612
2020 Q3	$3K	Hold	284	–	–	﹤0.01%	3447
2020 Q2	$4K	Buy	+284	New	+$3.3K	﹤0.01%	3401

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WHCM

Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

US Bancorp's VYGR Position: Q1 2021 in Review

US Bancorp sold out of Voyager Therapeutics (VYGR) in Q1 2021, closing a stake of 284 shares — an estimated $2K sold.

US Bancorp first reported a position in VYGR in Q2 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 101 funds tracked by Wall St. Rank hold VYGR as of Q1 2021.

US Bancorp reported no remaining Voyager Therapeutics position as of Q1 2021 after selling out during the quarter.
US Bancorp sold 284 Voyager Therapeutics shares in Q1 2021, an estimated $2K.
US Bancorp first reported a position in Voyager Therapeutics in Q2 2020 and held it in 3 quarters.
US Bancorp's Voyager Therapeutics position peaked at $4K in Q2 2020.
101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2021.

Based on US Bancorp's 13F filing for Q1 2021, filed 28 Apr 2021.